Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | HTR7 | P34969 | 4/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL11284383 | 0.99 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL13875120 | 0.92 | SIGMAR1 (0.69) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL13875122 | 0.90 | SIGMAR1 (0.71) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL6926448 | 0.88 | SIGMAR1 (0.64) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL11465528 | 0.88 | SIGMAR1 (0.76) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL270823 | 0.87 | DRD2 (0.64) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL2095954 | 0.85 | SIGMAR1 (0.69) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL21669396 | 0.85 | SIGMAR1 (0.69) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL8373462 | 0.85 | SIGMAR1 (0.69) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 | |
| SCHEMBL562405 | 0.85 | SIGMAR1 (0.69) | ALDH1A1SMN1; SMN2SIGMAR1HTR1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-20160095855-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.) (PL) | 2016-04-07 | — | — | US | disclosed |
| US-20150005316-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | SPROUT PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140031365-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | SPROUT PHARMACEUTICALS INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120270883-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | SPROUT PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-1428822-B1 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-RE41315-E1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | UNIVERSITA DI PISA, 40% (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | UNIVERSITA DI PISA, 40% (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | disclosed |
| EP-1240141-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240143-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046146-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046144-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0395312-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1999-05-12 | — | — | EP | disclosed |
| US-3929792-A | Phenylpiperazine derivatives, process for their preparation and applications thereof | BOUCHARA D EMILE | 1975-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031365-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | FLNB, FLNA, FLAD1 | ALDH1A1 1512/4885SMN1; SMN2 4548/4885SIGMAR1 950/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | ALDH1A1 1589/4885SMN1; SMN2 1033/4885SIGMAR1 1308/4885 |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | ALDH1A1 2082/4885SMN1; SMN2 960/4885SIGMAR1 5/4885 |
| US-20160095855-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | FLNB, FLNA, FLAD1 | ALDH1A1 1512/4885SMN1; SMN2 4548/4885SIGMAR1 950/4885 |
| US-20150005316-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | FLNB, FLNA, FLAD1 | ALDH1A1 1512/4885SMN1; SMN2 4548/4885SIGMAR1 950/4885 |
| US-20120270883-A1 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE | FLNB, FLNA, FLAD1 | ALDH1A1 1512/4885SMN1; SMN2 4548/4885SIGMAR1 950/4885 |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | ABCB1, ABCC1, ABCC2 | ALDH1A1 999/4885SMN1; SMN2 4864/4885SIGMAR1 728/4885 |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | ALDH1A1 2318/4885SMN1; SMN2 904/4885SIGMAR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.